Sciclone Pharmaceuticals

Sciclone Pharmaceuticals company information, Employees & Contact Information

Explore related pages

Sciclone Pharmaceuticals email format Sciclone Pharmaceuticals management contacts

Related company profiles:

SciClone is a US-based, China-focused specialty pharmaceutical company with a substantial revenue-generating and profitable commercial business and a broad, marketed product portfolio of differentiated therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders.

Company Details

Employees
112
Phone
(650) 358-3456
Email
ro****@****one.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
sciclone.com
Competitors
Teva Pharmaceuticals, Sanofi, OcuMension, Johnson & Johnson, Leica Microsystems, Amgen, Eisai Co., Ltd., BiBo Biopharma Engineering Co.,Ltd., Gloria Biosciences, Novartis.
Looking for a particular Sciclone Pharmaceuticals employee's phone or email?

Sciclone Pharmaceuticals Questions

News

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA - PR Newswire

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA PR Newswire

GL Capital raises continuation vehicle for China’s SciClone Pharmaceuticals - ION Analytics

GL Capital raises continuation vehicle for China’s SciClone Pharmaceuticals ION Analytics

Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone - ACN Newswire

Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone ACN Newswire

ADIA Invests in CV by GL Capital’s Pharmaceuticals - intlbm

ADIA Invests in CV by GL Capital’s Pharmaceuticals intlbm

ADIA Backs $230M Continuation Vehicle for SciClone in GL Capital-Led Deal - Funds Global MENA

ADIA Backs $230M Continuation Vehicle for SciClone in GL Capital-Led Deal Funds Global MENA

ADIA invests in continuation vehicle for GL Capital’s SciClone Pharmaceuticals - ZAWYA

ADIA invests in continuation vehicle for GL Capital’s SciClone Pharmaceuticals ZAWYA

Eisai grants exclusive development and distribution rights for Tasurgratinib in Greater China to SciClone Pharma - BioSpectrum Asia

Eisai grants exclusive development and distribution rights for Tasurgratinib in Greater China to SciClone Pharma BioSpectrum Asia

Tarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater China - Business Wire

Tarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater China Business Wire

Menarini and SciClone partner for Orserdu development in China - Pharmaceutical Technology

Menarini and SciClone partner for Orserdu development in China Pharmaceutical Technology

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer - The Korea Herald

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer The Korea Herald

ADIA takes lead on over $200m CV in latest GP-led secondaries play - Secondaries Investor

ADIA takes lead on over $200m CV in latest GP-led secondaries play Secondaries Investor

SciClone Pharmaceuticals Set for Privatization - Nasdaq

SciClone Pharmaceuticals Set for Privatization Nasdaq

SciClone starts trial of Covid-19 vaccine and Zadaxin combination - Clinical Trials Arena

SciClone starts trial of Covid-19 vaccine and Zadaxin combination Clinical Trials Arena

EpicentRx Inc. and SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001 in Greater China - PR Newswire

EpicentRx Inc. and SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001 in Greater China PR Newswire

Quartet guides HKD8.79bn privatisation bid for SciClone - Law.asia

Quartet guides HKD8.79bn privatisation bid for SciClone Law.asia

Pharmaceutical Industry Under U.S. Anti-Corruption Regulatory Spotlight - Global Compliance News

Pharmaceutical Industry Under U.S. Anti-Corruption Regulatory Spotlight Global Compliance News

Consortium Led By GL Capital Completes Acquisition Of SciClone - PR Newswire

Consortium Led By GL Capital Completes Acquisition Of SciClone PR Newswire

SciClone Enters Into Definitive Merger Agreement To Be Acquired By Consortium Led By GL Capital - PR Newswire

SciClone Enters Into Definitive Merger Agreement To Be Acquired By Consortium Led By GL Capital PR Newswire

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections - PR Newswire

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections PR Newswire

SciClone Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market - BioSpace

SciClone Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market BioSpace

New stock news | SciClone Pharmaceutical Group plans Hong Kong IPO, CSRC filing status is "supplementary materials". - 富途牛牛

New stock news | SciClone Pharmaceutical Group plans Hong Kong IPO, CSRC filing status is "supplementary materials". 富途牛牛

CC, Slaughters advise as HK-listed SciClone goes private for $1.13 bln - | Asian Legal Business

CC, Slaughters advise as HK-listed SciClone goes private for $1.13 bln | Asian Legal Business

SciClone Buys NovaMed In China Expansion - Asian Scientist Magazine

SciClone Buys NovaMed In China Expansion Asian Scientist Magazine

Enterprise — Essential business, finance and policy news from the Arab world - enterprise.news

Enterprise — Essential business, finance and policy news from the Arab world enterprise.news

PerkinElmer’s Sciclone G3 NGSx iQ workstation - Medical Buyer

PerkinElmer’s Sciclone G3 NGSx iQ workstation Medical Buyer

ADIA Joins Lead Role in GL Capital’s SciClone Continuation Vehicle - MSN

ADIA Joins Lead Role in GL Capital’s SciClone Continuation Vehicle MSN

Companies like Sciclone Pharmaceuticals

Amgen logo - Similar company to Sciclone Pharmaceuticals

Amgen

35.77K
Novartis logo - Similar company to Sciclone Pharmaceuticals

Novartis

79.78K
Sanofi logo - Similar company to Sciclone Pharmaceuticals

Sanofi

88.33K
Leica Microsystems logo - Similar company to Sciclone Pharmaceuticals

Leica Microsystems

2.38K
BiBo Biopharma Engineering Co.,Ltd. logo - Similar company to Sciclone Pharmaceuticals

Bibo Biopharma Engin...

16
Johnson & Johnson logo - Similar company to Sciclone Pharmaceuticals

Johnson & Johnson

100.89K
Teva Pharmaceuticals logo - Similar company to Sciclone Pharmaceuticals

Teva Pharmaceuticals

29.77K
Gloria Biosciences logo - Similar company to Sciclone Pharmaceuticals

Gloria Biosciences

3
Eisai Co., Ltd. logo - Similar company to Sciclone Pharmaceuticals

Eisai Co., Ltd.

672
OcuMension logo - Similar company to Sciclone Pharmaceuticals

Ocumension

24

Top Sciclone Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant